BioVisioN receives research grant within BioChancePLUS program
By investigating the action of several protease inhibitors in animal models, BioVisioN will discover biomarkers for drug efficacy and possible side effects that can be used in early and advanced stages of drug development thus allowing early selection of the optimal drug candidate and the proper selection of patients responding to the drug, speeding up drug development and contributing to cost reduction.
Most read news
Topics
Organizations
Other news from the department science
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.